- Home
- MYGN vs TRMD Comparison
MYGN vs TRMD Comparison
Compare MYGN & TRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TRMD
- Stock Information
- Founded
- MYGN 1991
- TRMD 1889
- Country
- MYGN United States
- TRMD United Kingdom
- Employees
- MYGN N/A
- TRMD N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TRMD Marine Transportation
- Sector
- MYGN Health Care
- TRMD Consumer Discretionary
- Exchange
- MYGN Nasdaq
- TRMD Nasdaq
- Market Cap
- MYGN 2.0B
- TRMD 1.9B
- IPO Year
- MYGN 1995
- TRMD N/A
- Fundamental
- Price
- MYGN $13.69
- TRMD $18.58
- Analyst Decision
- MYGN Hold
- TRMD Buy
- Analyst Count
- MYGN 12
- TRMD 1
- Target Price
- MYGN $23.92
- TRMD $48.00
- AVG Volume (30 Days)
- MYGN 904.0K
- TRMD 1.3M
- Earning Date
- MYGN 11-07-2024
- TRMD 11-07-2024
- Dividend Yield
- MYGN N/A
- TRMD 26.39%
- EPS Growth
- MYGN N/A
- TRMD N/A
- EPS
- MYGN N/A
- TRMD 7.70
- Revenue
- MYGN $823,600,000.00
- TRMD $1,641,593,000.00
- Revenue This Year
- MYGN $13.82
- TRMD N/A
- Revenue Next Year
- MYGN $4.59
- TRMD N/A
- P/E Ratio
- MYGN N/A
- TRMD $2.54
- Revenue Growth
- MYGN 12.15
- TRMD 3.90
- 52 Week Low
- MYGN $13.81
- TRMD $18.01
- 52 Week High
- MYGN $29.30
- TRMD $40.47
- Technical
- Relative Strength Index (RSI)
- MYGN 26.49
- TRMD 26.36
- Support Level
- MYGN $13.92
- TRMD $18.01
- Resistance Level
- MYGN $15.44
- TRMD $19.48
- Average True Range (ATR)
- MYGN 0.79
- TRMD 0.54
- MACD
- MYGN 0.03
- TRMD 0.08
- Stochastic Oscillator
- MYGN 3.06
- TRMD 14.73
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.